Ser51

Site Information
GGVkRsLsEQPVMDt SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 454289

In vivo Characterization
Methods used to characterize site in vivo:	immunoprecipitation ( 2 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 ) , mutation of modification site ( 2 ) , western blotting ( 2 )
Disease tissue studied:	bone cancer ( 2 ) , breast cancer ( 9 , 10 ) , breast ductal carcinoma ( 9 ) , HER2 positive breast cancer ( 4 ) , luminal A breast cancer ( 4 ) , luminal B breast cancer ( 4 ) , breast cancer, surrounding tissue ( 4 ) , breast cancer, triple negative ( 4 , 9 ) , cervical cancer ( 24 ) , cervical adenocarcinoma ( 24 ) , leukemia ( 18 ) , acute myelogenous leukemia ( 18 ) , hepatocellular carcinoma, surrounding tissue ( 23 ) , lung cancer ( 13 , 20 ) , non-small cell lung adenocarcinoma ( 13 ) , ovarian cancer ( 9 ) , pancreatic ductal adenocarcinoma ( 11 ) , multiple myeloma ( 22 ) , melanoma skin cancer ( 6 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 11 ) , 293 (epithelial) ( 8 ) , B lymphocyte-blood ( 22 ) , breast ( 4 , 9 ) , CL1-0 (pulmonary) ( 20 ) , CL1-1 (pulmonary) ( 20 ) , CL1-2 (pulmonary) ( 20 ) , CL1-5 (pulmonary) ( 20 ) , DG75 (B lymphocyte) ( 21 ) , Flp-In T-Rex-293 (epithelial) [PRKD1 (human), genetic knockin] ( 16 ) , Flp-In T-Rex-293 (epithelial) ( 16 ) , HaCaT (keratinocyte) ( 2 ) , HEK293T (epithelial) ( 2 ) , HeLa (cervical) ( 3 , 7 , 15 , 19 , 25 , 26 , 29 , 30 ) , HeLa S3 (cervical) ( 24 ) , hepatocyte-liver ( 23 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 10 ) , HMLER ('stem, breast cancer') ( 10 ) , hTERT-RPE1 (epithelial) ( 2 ) , Jurkat (T lymphocyte) ( 14 , 27 , 31 ) , K562 (erythroid) ( 15 , 28 ) , KG-1 (myeloid) ( 18 ) , lung ( 13 ) , ovary ( 9 ) , PANC-1 (pancreatic) [PRP4 (human), knockdown, Lentiviral introduced doxycycline-inducible PRP4 shRNA] ( 12 ) , PANC-1 (pancreatic) ( 12 ) , U2OS (bone cell) ( 2 ) , Vero E6-S ('epithelial, kidney') ( 1 ) , WM239A (melanocyte) ( 6 )

Upstream Regulation
Regulatory protein:	PRP4 (human) ( 12 )
Kinases, in vitro:	MAPKAPK2 (human) ( 2 )
Treatments:	ischemia ( 9 ) , metastatic potential ( 20 ) , nocodazole ( 24 ) , UV ( 2 )

Downstream Regulation
Effects of modification on RDBP:	molecular association, regulation ( 2 )
Effects of modification on biological processes:	transcription, induced ( 2 )
Induce interaction with:	14-3-3 epsilon (human) ( 2 )

References
1	Bouhaddou M, et al. (2020) The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 182 32645325 Curated Info
2	Borisova ME, et al. (2018) p38-MK2 signaling axis regulates RNA metabolism after UV-light-induced DNA damage. Nat Commun 9, 1017 29523821 Curated Info
3	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
4	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
5	Boeing S, et al. (2016) Multiomic Analysis of the UV-Induced DNA Damage Response. Cell Rep 15, 1597-1610 27184836 Curated Info
6	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
7	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
8	Wang R, et al. (2014) Global discovery of high-NaCl-induced changes of protein phosphorylation. Am J Physiol Cell Physiol 307, C442-54 24965592 Curated Info
9	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
10	Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90 24782546 Curated Info
11	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
12	Gao Q, et al. (2013) Evaluation of cancer dependence and druggability of PRP4 kinase using cellular, biochemical, and structural approaches. J Biol Chem 288, 30125-38 24003220 Curated Info
13	Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96 23911959 Curated Info
14	Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7 23749302 Curated Info
15	Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71 23186163 Curated Info
16	Franz-Wachtel M, et al. (2012) Global detection of protein kinase D-dependent phosphorylation events in nocodazole-treated human cells. Mol Cell Proteomics 11, 160-70 22496350 Curated Info
17	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
18	Weber C, Schreiber TB, Daub H (2012) Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells. J Proteomics 75, 1343-56 22115753 Curated Info
19	Nishioka T, Nakayama M, Amano M, Kaibuchi K (2012) Proteomic screening for Rho-kinase substrates by combining kinase and phosphatase inhibitors with 14-3-3ζ affinity chromatography. Cell Struct Funct 37, 39-48 22251793 Curated Info
20	Wang YT, et al. (2010) An informatics-assisted label-free quantitation strategy that depicts phosphoproteomic profiles in lung cancer cell invasion. J Proteome Res 9, 5582-97 20815410 Curated Info
21	Iliuk AB, et al. (2010) In-depth analyses of kinase-dependent tyrosine phosphoproteomes based on metal ion-functionalized soluble nanopolymers. Mol Cell Proteomics 9, 2162-72 20562096 Curated Info
22	Ge F, et al. (2010) Phosphoproteomic analysis of primary human multiple myeloma cells. J Proteomics 73, 1381-90 20230923 Curated Info
23	Han G, et al. (2010) Phosphoproteome analysis of human liver tissue by long-gradient nanoflow LC coupled with multiple stage MS analysis. Electrophoresis 31, 1080-9 20166139 Curated Info
24	Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3 20068231 Curated Info
25	Chen Y, et al. (2009) Combined integrin phosphoproteomic analyses and small interfering RNA--based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 69, 3713-20 19351860 Curated Info
26	Chen RQ, et al. (2009) CDC25B mediates rapamycin-induced oncogenic responses in cancer cells. Cancer Res 69, 2663-8 19276368 Curated Info
27	Mayya V, et al. (2009) Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal 2, ra46 19690332 Curated Info
28	Stokes M (2008) CST Curation Set: 4605; Year: 2008; Biosample/Treatment: cell line, K562/untreated; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]) Curated Info
29	Ruse CI, et al. (2008) Motif-specific sampling of phosphoproteomes. J Proteome Res 7, 2140-50 18452278 Curated Info
30	Imami K, et al. (2008) Automated Phosphoproteome Analysis for Cultured Cancer Cells by Two-Dimensional NanoLC-MS Using a Calcined Titania/C18 Biphasic Column. Anal Sci 24, 161-6 18187866 Curated Info
31	Rush J (2005) CST Curation Set: 713; Year: 2005; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) Akt Substrate Antibody Cat#: 9611 Curated Info